Physician
Medical Genetics
Dr. Neal J. Weinreb, MD
|
|
Give Review
Dr. Neal J. Weinreb is an expert in the field of Medical Genetics. He went to medical school at Mount Sinai School of Medicine. He has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Top Doctors: Florida". Dr. Neal J. Weinreb is a published doctor. He has 55 publications published. The most current publication "Gaucher disease: recommendations on diagnosis, evaluation, and monitoring." Neal Weinreb accepts Medicare.
Publications
- Recommendations for the use of eliglustat in the treatment of adults with Gaucher Disease type 1 in the United States.
- Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry Disease.
- Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.
- Oral small molecule therapy for lysosomal storage Diseases.
- A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher Disease type 1: safety and tolerabi...
- Erratum to: Long-term clinical outcomes in type 1 Gaucher Disease following 10 years of imiglucerase treatment.
- Long-term clinical outcomes in type 1 Gaucher Disease following 10 years of imiglucerase treatment.
- Preface: Gaucher disease and Cancer.
- Causes of Death Due to Hematological and Non-Hematological Cancers in 57 US Patients with Type 1 Gaucher Disease Who Were Never Treated with Enzyme Replacement Therapy.
- Gaucher Disease: a comprehensive review.
- Reducing selection bias in case-control studies from rare Disease registries.
- Early access experience with VPRIV(®): recommendations for 'core data' collection.
- JAK2V617F mutation and myeloproliferative malignancy in a patient with Type 1 Gaucher Disease.
- The incidence of Parkinsonism in patients with type 1 Gaucher Disease: data from the ICGG Gaucher Registry.
- Osteopenia in Gaucher Disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
- A validated Disease severity scoring system for adults with type 1 Gaucher Disease.
- Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher Disease: effect on incidence of avascular necrosis.
- Mesenchymal gaucho homing on the range.
- A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patien...
- Gaucher Disease: resetting the clinical and scientific agenda.
- Multiple myeloma and Gaucher genes.
- Phenotypic heterogeneity of N370S homozygotes with type I Gaucher Disease: an analysis of 798 patients from the ICGG Gaucher Registry.
- A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher Disease patients treated with imiglucerase.
- Life expectancy in Gaucher Disease type 1.
- Imiglucerase and its use for the treatment of Gaucher''s Disease.
- Management of non-neuronopathic Gaucher Disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone Disease monitoring.
- Improvement of bone Disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher Disease: results of a 48-month longitudinal c...
- Prevalence of type 1 Gaucher Disease in the United States.
- Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher Disease.
- The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher Disease.
- Guidance on the use of miglustat for treating patients with type 1 Gaucher Disease.
- Gaucher disease and Cancer incidence: a study from the Gaucher Registry.
- Individualization of long-term enzyme replacement therapy for Gaucher Disease.
- Gaucher Disease type 1: revised recommendations on evaluations and monitoring for adult patients.
- Introduction. Advances in Gaucher Disease: therapeutic goals and evaluation and monitoring guidelines.
- Therapeutic goals in the treatment of Gaucher Disease.
- Enzyme replacement therapy and monitoring for children with type 1 Gaucher Disease: consensus recommendations.
- Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher Disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
- Response of Gaucher bone Disease to enzyme replacement therapy.
- Skeletal aspects of Gaucher Disease: a review.
- Interruption in enzyme replacement therapy for Gaucher Disease.
- The Gaucher registry: demographics and Disease characteristics of 1698 patients with Gaucher Disease.
- Gaucher Disease: recommendations on diagnosis, evaluation, and monitoring.
- Euthanasia and doctor-assisted suicide: responses by oncologists and non-oncologists.
- Debility, unspecified: a terminal diagnosis.
- Acceleration of retarded growth in children with Gaucher Disease after treatment with alglucerase.
- Amyloidosis. An unusual complication of Gaucher''s Disease.
- Increased circulating levels of transcobalamin ii in gaucher''s Disease.
- Secondary gout associated with chronic myeloproliferative disorders.
- Spurious polycythemia.
- Torsion of the spleen as a rare cause of hypersplenism.
- Serious reaction after Konyne.
- The lysosomal localization of sphingolipid hydrolases.
- Patients with type 1 Gaucher Disease in South Florida, USA: demographics, genotypes, Disease severity and treatment outcomes.
Schools
SUNY Downstate Medical Center College Of Medicine
Bronx Municipal Hospital Center
Mt Sinai Hospital
Conditions Treated
- Anemia
- Bladder Cancer
- Breast Cancer
- Esophageal Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
- Medical Genetics
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Top Doctors: Florida
Education
-
Mount Sinai School of Medicine -
Albert Einstein College of Medicine at Jacobi Medical Center -
State University of New York Downstate Medical Center College of Medicine
Hospital
-
University of Miami Hospital
Drug Facts
| NPI NUMBER | 1760487177 | |
| NPPES Provider LastName | WEINREB | |
| NPPES Provider FirstName | NEAL | |
| NPPES Provider ZIPCode | 330655701 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 25.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1760487177 |
| Last Name Of The Provider | WEINREB |
| First Name Of The Provider | NEAL |
| View All |
Similar Doctors
|
|
Dr. Mislen S. Bauer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven Weiss, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Timothy Aliff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chris Grevengood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Jeff Luckey
This Doctor is OpenDoctor Recommended.
|
|
|
Janet W. Radford |